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KEYPOINTS:

1) FLT3
ITD tyrosine kinase (TK) inhibition impairs glycolysis and glucose utilization without equally affecting glutamine metabolism 2) Combined targeting of FLT3 TK activity and glutamine metabolism decreases expression analysis, we demonstrate that glutamine metabolism, through its ability to support both mitochondrial function and cellular redox metabolism, becomes a metabolic dependency of FLT3 ITD AML, specifically unmasked by FLT3-TKI treatment. We extend these findings to AML subtypes driven by other tyrosine kinase (TK) activating mutations, and validate the role of GLS as a clinically actionable therapeutic target in both primary AML and in vivo models. Our work highlights the role of metabolic adaptations as a resistance mechanism to several TKI, and suggests glutaminolysis as a therapeutically targetable vulnerability when combined with specific TKI in FLT3 ITD and other TK activating mutation driven leukemias.
INTRODUCTION
Acute myeloid leukemia (AML) is a highly heterogeneous disease at both the molecular and clinical level. Recent sequencing efforts have helped to categorize different subtypes based on their mutation profile and its putative effect on AML pathogenesis. Common subgroups include those carrying mutations in transcription factors and epigenetic regulators, cases carrying mutations in genes encoding for components of the spliceosome machinery and cohesin complexes, and those carrying mutations in signaling genes 1, 2 . Within the last group, activating mutations of tyrosine kinases (TK) are the most frequent and generally predict for a poor outcome 3 . In particular, mutations in the type-III receptor TK FLT3 are present in about 30% of AML patients, are mostly secondary to an internal tandem duplication (FLT3 ITD ) of the juxtamembrane domain and predict for an increased relapse rate following standard therapies and a poor prognosis 4 . Although FLT3 ITD mutations are acquired relatively late in leukemia evolution 1, 5 and are unable to produce an AML phenotype in animal models without collaborating mutations 6 , they are capable of conferring a state of oncogene addiction by activating survival pathways 7 . Their importance for the maintenance of the leukemic phenotype and as a relevant therapeutic target has also been confirmed by the results of a recent phase 3 randomized study (RATIFY), where a survival benefit for patients treated with FLT3 TK inhibitor (TKI) was demonstrated for the first time 8 , leading to recent FDA approval of the FLT3 inhibitor Midostaurin. However, despite our understanding of the role played by FLT3 ITD mutations in AML and the rational design of targeted inhibitors of their TK activity, the overall outcome of AML patients carrying FLT3 ITD mutations remains poor, suggesting that resistance mechanisms to targeted inhibitors might hinder the efficacy of these therapies 9 . Indeed mutations in the FLT3 TK domain have already been described as a frequent mechanism of resistance 7 . However, more recently, mutational analysis of patient samples obtained following relapse after FLT3-TKI treatment and a handful of preclinical studies have suggested that cellular adaptive mechanism might also play a role in FLT3-TKI resistance [10] [11] [12] [13] although these remain overall poorly defined.
FLT3
ITD mutations are known to activate survival/proliferation signaling pathways, including the PI3-kinase/AKT, Ras/MAP kinase and JAK/STAT pathways [14] [15] [16] [17] that are also known to directly or indirectly alter cell metabolism [18] [19] [20] . As a result, leukemias harboring FLT3 ITD mutations are often associated with a very proliferative and aggressive phenotype, high tumor bulk, and are accompanied by alterations in cellular metabolism to sustain this proliferative phenotype 4, 21 .
Metabolic reprogramming has emerged as a hallmark of transformed cells 22 and several reports have recently highlighted the role of specific metabolic enzymes and metabolites in normal hematopoietic stem cell homeostasis and leukemogenesis through both direct effects on energy production, macromolecule biosynthesis, and their ability to modulate redox balance, epigenetic regulation, and signaling pathways [23] [24] [25] [26] [27] [28] [29] . Moreover, metabolism is able to rapidly respond to changing conditions within a cell, and it has already been shown, in both solid cancers and hematological malignancies, that metabolic adaptations, under therapeutic selective pressure, can act as key resistance mechanisms to standard therapeutics 30, 31 .
In this work, we aimed to identify novel cellular adaptive resistance mechanisms to FLT3-TKI 
METHODS
An extended methods section is available in the online supplemental Data.
Cell culture
MV411, MOLM13, THP1, K562 were cultured in RPMI1640 (Sigma) supplemented with 10% dialyzed fetal bovine serum (FBS) (Sigma) and 1% penicillin/streptomycin/glutamine. . The gRNA sequences are listed in supplemental Methods.
Details are provided in supplemental Methods.
Liquid chromatography coupled to mass spectrometry (LC-MS) for metabolomics analysis
MV411 cells were plated at 0.5 x 10 6 cells per mL in media supplemented with uniformlylabelled- 13 Carbon (U-13 C 6 ) glucose (11 mM) or uniformly-labelled- 13 Carbon, 15 Nitrogen (U-13 C 5 , 15 N 2 ) glutamine (2 mM) (Cambridge Isotope laboratories) for 48 h before sampling.
Details of metabolite extraction and LC-MS analysis are provided in supplemental Methods.
Adult Primary Leukaemia and Cord Blood Samples Drug and Proliferation Assays
Human AML MNC were obtained from bone marrow or peripheral blood of patients. Normal CD34 samples were obtained from leukapheresis products of myeloma/lymphoma patients in bone marrow remission. Informed consent was obtained in accordance with the Declaration of Helsinki and the study was conducted under local ethical approval (REC 07-MRE05-44). Culture condition for methylcellulose and liquid culture assay of primary samples are as previously described 33 . , demonstrated significant enrichment for genes involved in several pathways, including some obviously relevant to AML biology (highlighted in the figure). Amongst these, metabolic pathways, including mostly genes involved in oxidative phosphorylation and the tricarboxylic acid (TCA) cycle were significantly enriched ( Figure 1B ). Amongst the top metabolic genes depleted following AC220 treatment, glutaminase (GLS) demonstrated the highest number of significantly depleted gRNA (all 5 guides out of 5 targeting the gene), indicating a strong synthetic lethal interaction with AC220 ( Figure 1C-D) . GLS is the first enzyme in glutamine catabolism, a metabolic pathway with well-established anaplerotic and biosynthetic roles in cancer cells 37 which also regulates the availability of substrates for both the TCA cycle and oxidative phosphorylation, two of the most affected pathways in our screen. Importantly, a potent and selective GLS inhibitor CB839 is currently being investigated in clinical trials 38 . Given the strong synthetic lethal interaction in the screen, its central role in regulating metabolic pathways shown to be affected in our screen and the availability of a clinical grade inhibitor, we decided to further investigate the role of GLS as a clinically relevant synthetic lethal pair in AC220-treated Table 2 ). The effects of AC220 on glycolysis were further confirmed by time-resolved metabolic profiling ( Figure 2F -G). As might be expected based on the profound antiproliferative effects of AC220 in the same cells (Supplemental Figure 3A -B), a reduction in total levels of most TCA cycle intermediates was also observed but this was less pronounced and the presence of 13 C 2 citrate and 13 C 3 aspartate isotopologues -products, respectively, of the activity of the anaplerotic enzymes pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC) -suggests that anaplerotic oxidative metabolism is still active in these cells ( Figure 2H -I and Supplemental Table 2 ). Moreover, the preservation of the unlabeled ( 13 C 0 ) and partially labelled ( 
In vivo experiments
The effects of combined GLS and TKI extend to other TK activating mutations, primary AML samples and in vivo models
To determine if a similar rewiring of metabolism occurs in leukemia driven by other activated TK that are amenable to targeted inhibition, we analyzed the metabolic consequences of inhibiting the chimeric BCR-ABL tyrosine kinase, which is central to the pathogenesis of chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia 50 , using its specific inhibitor imatinib 51 . Indeed, in a BCR-ABL positive cell line, imatinib treatment resulted in a reduction of glycolytic activity that also correlated with a decrease in gene expression levels of glycolytic enzymes ( Figure 5A-C) . Conversely, the effects on TCA cycle and glutathione metabolism genes were much less pronounced and although a significant reduction in both GLS and GLUD1 gene expression levels were noted following imatinib treatment, this was less than 50% and much smaller than those observed on glycolytic genes (Supplemental Figure 6A -C and Supplemental Figure 5D-F) .
Finally, we sought to confirm our findings in more physiological and clinically relevant models. Using primary AML samples from patients carrying a FLT3 ITD mutation, we found that AC220 treatment led to a reduction in glycolytic capacity, and combined treatment with AC220 and CB839 led to a reduction in basal oxygen consumption ( Figure 6A-B) . These effects correlated with a further reduction in the viability of FLT3 ITD primary samples following combined treatment that appeared proportional to the levels of FLT3 mutation, as measured by variant allele frequency (VAF), in each sample while similar effects were not observed in Finally GLS depletion was measured in vivo from human cells isolated from mouse organs.
Interestingly, in the shRNA GLS transduced cells, AC220 treatment resulted in a 50% reduction in GLS knockdown efficiency suggesting preferential killing of cells having lower levels of GLS expression (Supplemental Figure 7H) .
DISCUSSION
In this study we used orthogonal unbiased approaches including CRISPR/Cas9 synthetic lethality screen, metabolomics and gene expression analysis, to reveal that FLT3 ITD cells develop a metabolic dependency on glutamine metabolism following FLT3 TK inhibition. , and given that this function is not targeted by GLS inhibition, it is also plausible that these glutamine dependent metabolic pathways support cell survival following AC220
and combination treatment. . However an improved understanding of the molecular mechanisms leading to this metabolic phenotype and whether other anaplerotic substrates, such as fatty acids, also contribute to oxidative phosphorylation in therapy resistant cells might help to clarify the basis of resistance and help target it more effectively.
In conclusion, our results highlight the importance of 
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